Abstract
Major advancements in the treatment of cancer and immune-mediated diseases have been made over the past few decades with the introduction of a variety of new biologic and chemotherapeutic agents. Their use, however, has been associated with a variety of adverse cutaneous reactions, some of which may even lead to the discontinuation of the inciting therapy. In this chapter, the clinical and histologic features of the following reactions are discussed: granuloma annulare/interstitial granulomatous dermatitis and urticaria/cellulitis associated with tumor necrosis factor-alpha inhibitors, neutrophilic dermatoses associated with granulocyte colony-stimulating factor, injection site reactions of interferon, hand-foot skin reaction of kinase inhibitor (sorafenib, sunitinib), urticaria and infusion reactions of CD20 inhibitors, Richter’s syndrome associated with CD52 inhibitors, and pseudodermatomyositis associated with chronic hydroxyurea.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Adams AE, Zwicker J, Curiel C, Kadin ME, Falchuk KR, Drews R, Kupper TS. Aggressive cutaneous T-cell lymphomas after TNF-alpha blockade. J Am Acad Dermatol. 2004;51(4):660–2.
Agesta N, Zabala R, Diaz-Perez JL. Alopecia areata during interferon alpha-2b/ribavirin therapy. Dermatology. 2002;205(3):300–1.
Ahronowitz I, Harp J, Shinkai K. Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol. 2012;13(3):191–211. doi:10.2165/11595240-000000000-00000.
Alonso-Perez A, Ballestero-Diez M, Fraga J, Garcia-Diez A, Fernandez-Herrera J. Cutaneous sarcoidosis by interferon therapy in a patient with melanoma. J Eur Acad Dermatol Venereol. 2006;20(10):1328–9.
Alvarez-Ruiz S, Penas PF, Fernandez-Herrera J, Sanchez-Perez J, Fraga J, Garcia-Diez A. Maculopapular eruption with enlarged macrophages in eight patients receiving G-CSF or GM-CSF. J Eur Acad Dermatol Venereol. 2004;18(3):310–3.
Arrue I, Saiz A, Ortiz-Romero PL, Rodriguez-Peralto JL. Lupus-like reaction to interferon at the injection site: report of five cases. J Cutan Pathol. 2007;34 Suppl 1:18–21.
Azad NS, Aragon-Ching JB, Dahut WL, Gutierrez M, Figg WD, Jain L, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res. 2009;15(4):1411–6. doi:10.1158/1078-0432.CCR-08-1141.
Bahadoran P, Castanet J, Lacour JP, Perrin C, Del Giudice P, Mannocci N, et al. Pseudo-dermatomyositis induced by long-term hydroxyurea therapy: report of two cases. Br J Dermatol. 1996;134(6):1161–3.
Baron S, Tyring SK, Fleischmann Jr WR, Coppenhaver DH, Niesel DW, Klimpel GR, et al. The interferons. Mechanisms of action and clinical applications. JAMA. 1991;266(10):1375–83.
Batycka-Baran A, Flaig M, Molin S, Ruzicka T, Prinz JC. Etanercept-induced injection site reactions: potential pathomechanisms and clinical assessment. Expert Opin Drug Saf. 2012;11(6):911–21. doi:10.1517/14740338.2012.727796.
Bauer K, Rancea M, Roloff V, Elter T, Hallek M, Engert A, Skoetz N. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia. Cochrane Database Syst Rev. 2012;11:CD008079. doi:10.1002/14651858.CD008079.pub2.
Beard JS, Smith KJ, Skelton HG. Combination chemotherapy with 5-fluorouracil, folinic acid, and alpha-interferon producing histologic feature of graft-versus-host disease. J Am Acad Dermatol. 1993;29(2 Pt 2):325–30.
Bidyasar S, Montoya M, Suleman K, Markowitz AB. Sweet syndrome associated with granulocyte colony-stimulating factor. J Clin Oncol. 2008;26(26):4355–6. doi:10.1200/JCO.2008.16.2933.
Borrás-Blasco J, Gracia-Perez A, Rosique-Robles JD, Nuñez-Cornejo C, Casterá MD, Abad FJ. Urticaria due to etanercept in a patient with psoriatic arthritis. South Med J. 2009;102(3):304–5. doi:10.1097/SMJ.0b013e31819450e7.
Bouaziz JD, Ortonne N, Giustiniani J, Schiavon V, Huet D, Bagot M, Bensussan A. Circulating natural killer lymphocytes are potential cytotoxic effectors against autologous malignant cells in sezary syndrome patients. J Invest Dermatol. 2005;125(6):1273–8.
Bovenschen HJ, Tjioe M, Vermaat H, de Hoop D, Witteman BM, Janssens RW, et al. Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biologicals. Br J Dermatol. 2006;154:880–4.
Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007;25(7):884–96.
Christian MM, Diven DG, Sanchez RL, Soloway RD. Injection site vasculitis in a patient receiving interferon alfa for chronic hepatitis C. J Am Acad Dermatol. 1997;37(1):118–20.
Chu D, Lacouture ME, Fillos T, Wu S. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol. 2008;47(2):176–86. doi:10.1080/02841860701765675.
Chu P, Connolly MK, LeBoit PE. The histopathologic spectrum of palisaded neutrophilic and granulomatous dermatitis in patients with collagen vascular disease. Arch Dermatol. 1994;130(10):1278–83.
Coca A, Sanz I. Updates on B-cell immunotherapies for systemic lupus erythematosus and Sjogren’s syndrome. Curr Opin Rheumatol. 2012;24(5):451–6. doi:10.1097/BOR.0b013e32835707e4.
Cohen PR. Sweet’s syndrome – a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis. 2007;2:34.
Cohen Y, Da’as N, Libster D, Amir G, Berrebi A, Polliack A. Large – cell transformation of chronic lymphocytic leukemia and follicular lymphoma during or soon after treatment with fludarabine-rituximab-containing regimens: natural history- or therapy-related complication? Eur J Haematol. 2002;68(2):80–3.
Colombel JF, Loftus Jr EV, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126(1):19–31.
Couderc LJ, Philippe B, Franck N, Balloul-Delclaux E, Lessana-Leibowitch M. Necrotizing vasculitis and exacerbation of psoriasis after granulocyte colony-stimulating factor for small cell lung carcinoma. Respir Med. 1995;89(3):237–8.
Dacey MJ, Callen JP. Hydroxyurea-induced dermatomyositis-like eruption. J Am Acad Dermatol. 2003;48(3):439–41.
Dalmau J, Pimentel CL, Puig L, Peramiquel L, Roe E, Alomar A. Cutaneous necrosis after injection of polyethylene glycol-modified interferon alfa. J Am Acad Dermatol. 2005;53(1):62–6.
Demirturk N, Aykin N, Demirdal T, Cevik F. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-INF and ribavirin. Eur J Dermatol. 2006;16(5):579–80.
Deng A, Harvey V, Sina B, Strobel D, Badros A, Junkins-Hopkins JM, et al. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. Arch Dermatol. 2006;142(2):198–202.
Dereure O, Rason-Peyron N, Larrey D, Blanc F, Guilhou JJ. Diffuse inflammatory lesions in patients treated with interferon alpha and ribavirin for hepatitis C: a series of 20 patients. Br J Dermatol. 2002;147(6):1142–6.
Detmar U, Agathos M, Nerl C. Allergy of delayed type to recombinant interferon alpha 2c. Contact Dermatitis. 1989;20(2):149–50.
Dillman RO. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev. 1999;18(4):465–71.
Dong F, Brynes RK, Tidow N, Welte K, Löwenberg B, Touw IP. Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl J Med. 1995;333(8):487–93.
Errante D, Bernardi D, Bianco A, De Nardi S, Salvagno L. Rituximab-related urticarial reaction in a patient treated for primary cutaneous B-cell lymphoma. Ann Oncol. 2006;17(11):1720–1.
Esser AC, Abril A, Fayne S, Doyle JA. Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab. J Am Acad Dermatol. 2004;50(5 Suppl):S75–7.
Faguer S, Launay F, Ysebaert L, Mailhol C, Estines-Chartier O, Lamant L, Paul C. Acute cutaneous T-cell lymphoma transformation during treatment with alemtuzumab. Br J Dermatol. 2007;157(4):841–2.
Fantini F, Padalino C, Gualdi G, Monari P, Giannetti A. Cutaneous lesions as initial signs of interferon alpha-induced sarcoidosis: report of three new cases and review of the literature. Dermatol Ther. 2009;22 Suppl 1:S1–7. doi:10.1111/j.1529-8019.2009.01263.x.
Fukutoku M, Shimizu S, Ogawa Y, Takeshita S, Masaki Y, Arai T, et al. Sweet’s syndrome during therapy with granulocyte colony-stimulating factor in a patient with aplastic anaemia. Br J Haematol. 1994;86(3):645–8.
Fukuyama S, Kajiwara E, Suzuki N, Miyazaki N, Sadoshima S, Onoyama K. Systemic lupus erythematosus after alpha-interferon therapy for chronic hepatitis C: a case report and review of the literature. Am J Gastroenterol. 2000;95(1):310–2.
González-López MA, MartÃnez-Taboada VM, González-Vela MC, Blanco R, Fernández-Llaca H, RodrÃguez-Valverde V, Val-Bernal JF. Recall injection-site reactions associated with etanercept therapy: report of two new cases with immunohistochemical analysis. Clin Exp Dermatol. 2007;32(6):672–4.
Hadjinicolaou AV, Nisar MK, Parfrey H, Chilvers ER, Ostör AJ. Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology (Oxford). 2012;51(4):653–62. doi:10.1093/rheumatology/ker290.
Hagen JW, Magro CM, Crowson AN. Emerging adverse cutaneous drug reactions. Dermatol Clin. 2012;30(4):695–730. doi:10.1016/j.det.2012.06.016.
Hale G, Swirsky D, Waldmann H, Chan LC. Reactivity of rat monoclonal antibody CAMPATH-1 with human leukaemia cells and its possible application for autologous bone marrow transplantation. Br J Haematol. 1985;60(1):41–8.
Halverstam CP, Lebwohl M. Nonstandard and off-label therapies for psoriasis. Clin Dermatol. 2008;26(5):546–53. doi:10.1016/j.clindermatol.2007.10.023.
Heinzerling LM, Urbanek M, Funk JO, Peker S, Bleck O, Neuber K, et al. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer. 2000;89(8):1835–44.
Hertl MS, Haendle I, Schuler G, Hertl M. Rapid improvement of recalcitrant disseminated granuloma annulare upon treatment with the tumour necrosis factor-alpha inhibitor, infliximab. Br J Dermatol. 2005;152(3):552–5.
Isaacs A, Lindemann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci. 1957;147(927):258–67.
Jacobi U, Waibler E, Schulze P, Sehouli J, Oskay-Ozcelik G, Schmook T, et al. Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome? Ann Oncol. 2005;16(7):1210–1.
Jain KK. Cutaneous vasculitis associated with granulocyte colony-stimulating factor. J Am Acad Dermatol. 1994;31(2 Pt 1):213–5.
Jamroziak K, Grzybowska-Izydorczyk O, Jesionek-Kupnicka D, Gora-Tybor J, Robak T. Poor prognosis of Hodgkin variant of Richter transformation in chronic lymphocytic leukemia treated with cladribine. Br J Haematol. 2012;158(2):286–8; author reply 289. doi:10.1111/j.1365-2141.2012.09127.x.
Janssens A, Berth M, De Paepe P, Verhasselt B, Van Roy N, Noens L, et al. EBV negative Richter’s syndrome from a coexistent clone after savage treatment with alemtuzumab in a CLL patient. Am J Hematol. 2006;81(9):706–12.
Johnson ML, Grimwood RE. Leukocyte colony-stimulating factors. A review of associated neutrophilic dermatoses and vasculitides. Arch Dermatol. 1994;130(1):77–81.
Karlsson C, Norin S, Kimby E, Sander B, Porwit Macdonald A, et al. Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation. Leukemia. 2006;20(12):2204–7.
Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med. 2006;354(19):2034–45.
Kawakami T, Ohashi S, Kawa Y, Takahama H, Ito M, Soma Y, Mizoguchi M. Elevated serum granulocyte colony-stimulating factor levels in patients with active phase of sweet syndrome and patients with active behcet disease: implication in neutrophil apoptosis dysfunction. Arch Dermatol. 2004;140(5):570–4.
Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345(15):1098–104.
Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99(10):3554–61.
Kennedy BJ, Smith LR, Goltz RW. Skin changes secondary to hydroxyurea therapy. Arch Dermatol. 1975;111(2):183–7.
Ketikoglou I, Karatapanis S, Elefsiniotis I, Kafiri G, Moulakakis A. Extensive psoriasis induced by pegylated interferon alpha-2b treatment for Hepatitis B. Eur J Dermatol. 2005;15(2):107–9.
Kim SY, Solomon DH. Tumor necrosis factor blockade and the risk of viral infection. Nat Rev Rheumatol. 2010;6(3):165–74. doi:10.1038/nrrheum.2009.279.
Kokudo N, Nakajima J, Hatano E, Numata K. Current status of hepatocellular carcinoma treatment in Japan: practical use of sorafenib (Nexavar®). Clin Drug Investig. 2012;32 Suppl 2:25–35. doi:10.2165/1163023-S0-000000000-00000.
Kollias G, Douni E, Kassiotis G, Kontoyiannis D. The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Ann Rheum Dis. 1999;58 Suppl 1:I32–9.
Kong HH, Sibaud V, Chanco Turner ML, Fojo T, Hornyak TJ, Chevreau C. Sorafenib-induced eruptive melanocytic lesions. Arch Dermatol. 2008;144(6):820–2. doi:10.1001/archderm.144.6.820.
Koontz D, Alshekhlee A. Embolia cutis medicamentosa following interferon beta injection. Mult Scler. 2007;13(9):1203–4.
Krainick U, Kantarjian H, Broussard S, Talpaz M. Local cutaneous necrotizing lesions associated with interferon injections. J Interferon Cytokine Res. 1998;18(10):823–7.
Lacouture ME, Reilly LM, Gerami P, Guitart J. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol. 2008;19(11):1955–61. doi:10.1093/annonc/mdn389.
Lang AM, Norland AM, Schuneman RL, Tope WD. Localized interferon alfa-2b-induced alopecia. Arch Dermatol. 1999;135(9):1126–8.
Lee L, Kukreti V. Rituximab-induced coronary vasospasm. Case Rep Hematol. 2012;2012:984986. doi:10.1155/2012/984986.
Lee A, Skelly ME, Kingma DW, Medeiros LJ. B-cell chronic lymphocytic leukemia followed by high grade T-cell lymphoma. An unusual variant of Richter’s syndrome. Am J Clin Pathol. 1995;103(3):348–52.
Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol. 2009;161(5):1045–51. doi:10.1111/j.1365-2133.2009.09290.x.
Lenihan DJ, Alencar AJ, Yang D, Kurzrock R, Keating MJ, Duvic M. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome. Blood. 2004;104(3):655–8.
Lewerin C, Mobacken H, Nilsson-Ehle H, Swolin B. Bullous pyoderma gangrenosum in a patient with myelodysplastic syndrome during granulocyte colony-stimulating factor therapy. Leuk Lymphoma. 1997;26(5–6):629–32.
Long D, Thiboutot DM, Majeski JT, Vasily DB, Helm KF. Interstitial granulomatous dermatitis with arthritis. J Am Acad Dermatol. 1996;34(6):957–61.
Lowndes S, Darby A, Mead G, Lister A. Stevens-Johnson syndrome after treatment with rituximab. Ann Oncol. 2002;13(12):1948–50.
Luton K, Garcia C, Poletti E, Koester G. Nicolau syndrome: three cases and review. Int J Dermatol. 2006;45(11):1326–8.
Magro CM, Crowson AN, Schapiro BL. The interstitial granulomatous drug reaction: a distinctive clinical and pathological entity. J Cutan Pathol. 1998;25(2):72–8.
Maloney DG. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med. 2012;366(21):2008–16. doi:10.1056/NEJMct1114348.
Miall FM, Harman K, Kennedy B, Dyer MJ. Pyoderma gangrenosum complicating pegylated granulocyte colony-stimulating factor in Hodgkin lymphoma. Br J Haematol. 2006;132(1):115–6.
Montoto S, Bosch F, Estrach T, Blade J, Nomdedeu B, Nontserrat E. Pyoderma gangrenosum triggered by alpha2b-interferron in a patient with chronic granulocytic leukemia. Leuk Lymphoma. 1998;30(1–2):199–202.
Moore MM, Elpern DJ, Carter DJ. Severe, generalized nummular eczema secondary to interferon alfa-2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Arch Dermatol. 2004;140(2):215–7.
Moots RJ, Naisbett-Groet B. The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review. Rheumatology (Oxford). 2012;51(12):2252–61. doi:10.1093/rheumatology/kes217.
Moustou AE, Matelovits A, Dessinioti C, Antoniou C, Sfikakis PP, Stratigos AJ. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol. 2009;61(3):486–504. doi:10.1016/j.jaad.2008.10.060.
Nagore E, Insa A, Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia (‘hand-foot’) syndrome. Incidence, recognition and management. Am J Clin Dermatol. 2000;1(4):225–34.
Omair MA, Alnaqbi KA, Lee P. Rituximab in a patient with ankylosing spondylitis with demyelinating disease: a case report and review of the literature. Clin Rheumatol. 2012;31(8):1259–61. doi:10.1007/s10067-012-2002-8.
Oskay T, Kutluay L, Ozyilkan O. Dermatomyositis-like eruption after long-term hydroxyurea therapy for polycythemia vera. Eur J Dermatol. 2002;12(6):586–8.
Ostlere LS, Harris D, Prentice HG, Rustin MHA. Widespread folliculitis induced by human granulocyte-colony stimulating factor therapy [Letter]. Br J Dermatol. 1992;127:193.
Papi M, Didona B, DePita O, Abruzzese E, Stasi R, Papa G, Cavalieri R. Multiple skin tumors on light-exposed areas during long-term treatment with hydroxyurea. J Am Acad Dermatol. 1993;28(3):485–6.
Parameswaran N, Patial S. Tumor necrosis factor-α signaling in macrophages. Crit Rev Eukaryot Gene Expr. 2010;20(2):87–103.
Paydas S, Sahin B, Seyrek E, Soylu M, Gonlusen G, Acar A, Tuncer I. Sweet syndrome associated with G-CSF. Br J Dermatol. 1993;85(1):191–2.
Pinto JM, Marques MS, Correia TE. Lichen planus and leukocytoclastic vasculitis induced by interferon alpha-2b in a subject with HCV-related chronic active hepatitis. J Eur Acad Dermatol. 2003;17(2):193–5.
Prendiville J, Thiessen P, Mallory SB. Neutrophilic dermatoses in two children with idiopathic neutropenia: association with granulocyte colony-stimulating factor (G-CSF) therapy. Pediatr Dermatol. 2001;18(5):417–21.
Quesada JR, Gutterman JU. Psoriasis and alpha-interferon. Lancet. 1986;1(8496):1466–8.
Raymond AK, Puri PK, Selim MA, Tyler DS, Nelson KC. Regional squamous cell carcinomas following sorafenib therapy and isolated limb infusion for regionally advanced metastatic melanoma of the limb. Arch Dermatol. 2010;146(12):1438–9. doi:10.1001/archdermatol.2010.367.
Reuss-Borst MA, Pawelec G, Saal JG, Horny HP, Müller CA, Waller HD. Sweet’s syndrome associated with myelodysplasia: possible role of cytokines in the pathogenesis of the disease. Br J Haematol. 1993;84(2):356–8.
Rey J, Wickenhauser S, Ivanov V, Coso D, Gastaut JA, Bouabdallah R. A case of rituximab-related urticarial reaction in cutaneous B-cell lymphoma. J Eur Acad Dermatol Venereol. 2009;23(2):210. doi:10.1111/j.1468-3083.2008.02792.x.
Richard M, Truchetet F, Friedel J, Leclech C, Heid E. Skin lesions simulating chronic dermatomyositis during long-term hydroxyurea therapy. J Am Acad Dermatol. 1989;21(4 Pt 1):797–9.
Richter MN. Generalized reticular cell sarcoma of lymph nodes associated with lymphatic leukemia. Am J Pathol. 1928;4(4):285–92.7.
Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005;6(7):491–500.
Robert C, Arnault JP, Mateus C. RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol. 2011;23(2):177–82. doi:10.1097/CCO.0b013e3283436e8c.
Robertson LE, Pugh W, O’Brien S, Kantarjian H, Hirsch-Ginsberg C, Cork A, et al. Richter’s syndrome: a report on 39 patients. J Clin Oncol. 1993;11(10):1985–9.
Robinson AB, Reed AM. Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. Nat Rev Rheumatol. 2011;7(11):664–75. doi:10.1038/nrrheum.2011.139.
Rocamora V, Puig L, Alomar A. Dermatomyositis-like eruption following hydroxyurea therapy. J Eur Acad Dermatol Venereol. 2000;14(3):227–8.
Rosenbaum SE, Wu S, Newman MA, West DP, Kuzel T, Lacouture ME. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer. 2008;16(6):557–66. doi:10.1007/s00520-008-0409-1.
Ross HJ, Moy LA, Kaplan R, Figlin RA. Bullous pyoderma gangrenosum after granulocyte colony-stimulating factor treatment. Cancer. 1991;68(2):441–3.
Rossi D, Gaidano G. Richter syndrome: molecular insights and clinical perspectives. Hematol Oncol. 2009;27(1):1–10. doi:10.1002/hon.880.
Salihoglu A, Ozbalak M, Keskin D, Tecimer T, Soysal T, Ferhanoglu B. An unusual presentation of a chronic lymphocytic leukemia patient with 17p deletion after reduced-intensity transplantation: Richter syndrome and concomitant graft-versus-host disease-case report. Transplant Proc. 2013;S0041-1345(12):1304–8. doi:10.1016/j.transproceed.2012.12.001.
Sanders S, Busam K, Tahan SR, Johnson RA, Sachs D. Granulomatous and suppurative dermatitis at interferon alfa injection sites: report of 2 cases. J Am Acad Dermatol. 2002;46(4):611–6.
Saraceno R, Teoli M, Chimenti S. Hydroxyurea associated with concomitant occurrence of diffuse longitudinal melanonychia and multiple squamous cell carcinomas in an elderly subject. Clin Ther. 2008;30(7):1324–9.
Selmi C, Lleo A, Zuin M, Podda M, Rossaro L, Gershwin ME. Interferon alpha and its contribution to autoimmunity. Curr Opin Investig Drugs. 2006;7(5):451–6.
Senet P, Aractingi S, Porneuf M, Perrin P, Duterque M. Hydroxyurea-induced dermatomyositis-like eruption. Br J Dermatol. 1995;133(3):455–9.
Sfikakis PP, Kollias G. Tumor necrosis factor biology in experimental and clinical arthritis. Curr Opin Rheumatol. 2003;15(4):380–6.
Shpiro D, Gilat D, Fisher-Feld L, Shemer A, Gold I, Trau H. Pyoderma gangrenosum successfully treated with perilesional granulocyte-macrophage colony stimulating factor. Br J Dermatol. 1998;138(2):368–9.
Sigal M, Crickx B, Blanchet P, Perron J, Simony J, Belaïch S. Cutaneous lesions induced by long-term use of hydroxyurea. Ann Dermatol Venereol. 1984;111(10):895–900 [Article in French].
Singer EA, Gupta GN, Srinivasan R. Targeted therapeutic strategies for the management of renal cell carcinoma. Curr Opin Oncol. 2012;24(3):284–90. doi:10.1097/CCO.0b013e328351c646.
Skytta E, Phjankoski H, Savolainen A. Etanercept and urticaria in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2000;18:533–4.
Smith KJ, Haley H, Hamza S, Skelton HG. Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors. Dermatol Surg. 2009;35(11):1766–70. doi:10.1111/j.1524-4725.2009.01289.x.
Spiekermann K, Roesler J, Emmendoerffer A, Elsner J, Welte K. Functional features of neutrophils induced by G-CSF and GM-CSF treatment: differential effects and clinical implications. Leukemia. 1997;11(4):466–78.
Stasi R, Cantonetti M, Abruzzesse E, Papi M, Didona B, Cavalieri R, Papa G. Multiple skin tumors in long-term treatment with hydroxyurea. Eur J Dermatol. 1992;48(2):121–2.
Stewart LR, George S, Hamacher KL, Hsu S. Granuloma annulare of the palms. Dermatol Online J. 2011;17(5):7.
Suehiro M, Kishimoto S, Wakabayashi T, Ikeuchi A, Miyake H, Takenaka H, et al. Hydroxyurea dermopathy with a dermatomyositis-like eruption and a large leg ulcer. Br J Dermatol. 1998;139(4):748–9.
Sweet RD. An acute febrile neutrophilic dermatosis. Br J Dermatol. 1964;76:349–56.
Tai YJ, Tam M. Fixed drug eruption with interferon-beta-1b. Australas J Dermatol. 2005;46(3):154–7.
Tohda S, Morio T, Suzuki T, Nagata K, Kamiyama T, Imai Y, et al. Richter syndrome with two B cell clones possessing different surface immunoglobulins and immunoglobulin gene rearrangements. Am J Hematol. 1990;35(1):32–6.
Tomasiewicz K, Modzewska R, Semczuk G. Vitiligo associated with pegylated interferon and ribavirin treatment of patients with chronic hepatitis C: a case report. Adv Ther. 2006;23(1):139–42.
Valks R, Vargas E, Munoz E, Fernandez-Herrera J, Garcia-Diez A, Fraga J. Dermal infiltrate of enlarged macrophages in patients receiving chemotherapy. J Cutan Pathol. 1998;25(5):259–64.
Van der Kolk LE, Grillo-Lopez AJ, Baars JW, Hack CE, van Oers MH. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol. 2001;115(4):807–11.
van Husen M, Kemper MJ. New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome. Pediatr Nephrol. 2011;26(6):881–92. doi:10.1007/s00467-010-1717-5. Epub 2011 Jan 13.
van Kamp H, van den Berg E, Timens W, Kraaijenbrink RA, Halie MR, Daenen SM. Sweet’s syndrome in myeloid malignancy: a report of two cases. Br J Haematol. 1994;86(2):415–7.
Voulgari PV, Markatseli TE, Exarchou SA, Zioga A, Drosos AA. Granuloma annulare induced by anti-tumour necrosis factor therapy. Ann Rheum Dis. 2008;67(4):567–70.
Walker DC, Cohen PR. Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet’s syndrome. J Am Acad Dermatol. 1996;34(5 Pt 2):918–23.
White JM, Mufti GJ, Salisbury JR, du Vivier AW. Cutaneous manifestations of granulocyte colony-stimulating factor. Clin Exp Dermatol. 2006;31(2):206–7.
Wilhelm S, Chien DS. Bay 43-9006: preclinical data. Curr Pharm Des. 2002;8(25):2255–7.
Williams VL, Cohen PR. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int J Dermatol. 2011;50(5):619–25. doi:10.1111/j.1365-4632.2011.04871.x.
Winfield H, Lain E, Horn T, Hoskyn J. Eosinophilic cellulitis-like reaction to subcutaneous etanercept injection. Arch Dermatol. 2006;142:218–20.
Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999;94(7):2217–24.
Zeltser R, Valle L, Tanck C, Holyst M, Ritchlin C, Gaspari AA. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. Arch Dermatol. 2001;137(7):893–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Lee, J.J., Hoang, M.P. (2014). Cutaneous Lymphoid Infiltrates in Patients Receiving Biologic Modifiers. In: Cualing, H., Kadin, M., Hoang, M., Morgan, M. (eds) Cutaneous Hematopathology. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0950-6_15
Download citation
DOI: https://doi.org/10.1007/978-1-4939-0950-6_15
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-0949-0
Online ISBN: 978-1-4939-0950-6
eBook Packages: MedicineMedicine (R0)